FDA granted accelerated approval to Farydak (panobinostat) for the treatment of multiple myeloma. The FDA had previously granted Farydak priority review and an orphan product designation.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
